TRDAEntrada Therapeutics Inc
Entrada Therapeutics, Inc. is a clinical-stage biopharmaceutical company aiming to transform the lives of patients by establishing a new class of medicines that engage intracellular targets that have long been considered inaccessible. The company’s Endosomal Escape Vehicle (EEV) therapeutics are designed to enable the efficient intracellular delivery of a wide range of therapeutics into a variety of organs and tissues, resulting in an improved therapeutic index. Through this proprietary, versatile and modular approach, Entrada is advancing a robust development portfolio of RNA- and protein-based programs for the potential treatment of neuromuscular and ocular diseases, among others. The company’s oligonucleotide programs are in development for the potential treatment of people living with Duchenne who are exon 44, 45, 50 and 51 skipping amenable. Entrada has partnered to develop a clinical-stage program, VX-670, for myotonic dystrophy type 1. Entrada Therapeutics was founded by Dehua Pei in 2016 and is headquartered in Boston, MA.
Sector:
Health Technology
Industry:
Biotechnology
Employees:
183
Frequently Asked Questions
What is Market Cap of Entrada Therapeutics Inc?
What is the 52-week high for Entrada Therapeutics Inc?
What is the 52-week low for Entrada Therapeutics Inc?
What is Entrada Therapeutics Inc stock price today?
What was Entrada Therapeutics Inc stock price yesterday?
What is the PE ratio of Entrada Therapeutics Inc?
What is the Price-to-Book ratio of Entrada Therapeutics Inc?
What is the 50-day moving average of Entrada Therapeutics Inc?
How many employess does Entrada Therapeutics Inc has?